Rutabaga Capital Management LLC MA lessened its stake in Haemonetics Co. (NYSE:HAE) by 20.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 178,976 shares of the medical instruments supplier’s stock after selling 47,100 shares during the period. Haemonetics accounts for about 2.4% of Rutabaga Capital Management LLC MA’s portfolio, making the stock its 18th largest position. Rutabaga Capital Management LLC MA’s holdings in Haemonetics were worth $10,395,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Janney Montgomery Scott LLC increased its stake in Haemonetics by 3.8% in the 3rd quarter. Janney Montgomery Scott LLC now owns 51,256 shares of the medical instruments supplier’s stock worth $2,300,000 after buying an additional 1,879 shares during the period. Rhumbline Advisers grew its holdings in Haemonetics by 2.1% during the 3rd quarter. Rhumbline Advisers now owns 104,669 shares of the medical instruments supplier’s stock worth $4,696,000 after acquiring an additional 2,145 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Haemonetics by 3.7% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 589,379 shares of the medical instruments supplier’s stock worth $26,446,000 after acquiring an additional 20,925 shares in the last quarter. Boston Advisors LLC grew its holdings in Haemonetics by 83.8% during the 3rd quarter. Boston Advisors LLC now owns 50,825 shares of the medical instruments supplier’s stock worth $2,281,000 after acquiring an additional 23,180 shares in the last quarter. Finally, TCW Group Inc. bought a new position in Haemonetics during the 3rd quarter worth about $457,000.

Several brokerages have issued reports on HAE. TheStreet cut shares of Haemonetics from a “b” rating to a “c+” rating in a report on Tuesday, February 6th. Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $78.00 target price on the stock in a report on Friday. Morgan Stanley increased their target price on shares of Haemonetics from $74.00 to $77.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Barrington Research reiterated an “outperform” rating and set a $71.00 target price (up from $57.00) on shares of Haemonetics in a report on Wednesday, February 7th. Finally, Jefferies Group reiterated a “buy” rating and set a $80.00 target price on shares of Haemonetics in a report on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $71.33.

Shares of Haemonetics Co. (NYSE:HAE) opened at $68.70 on Monday. Haemonetics Co. has a 1-year low of $37.07 and a 1-year high of $72.33. The firm has a market cap of $3,671.85, a PE ratio of -202.05, a PEG ratio of 3.40 and a beta of 1.06. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.82 and a quick ratio of 1.33.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.18. Haemonetics had a negative net margin of 1.94% and a positive return on equity of 12.39%. The business had revenue of $234.04 million for the quarter, compared to analysts’ expectations of $227.79 million. During the same period last year, the business earned $0.43 EPS. The company’s revenue was up 2.7% compared to the same quarter last year. sell-side analysts predict that Haemonetics Co. will post 1.87 earnings per share for the current fiscal year.

Haemonetics declared that its Board of Directors has approved a stock buyback plan on Tuesday, February 6th that authorizes the company to repurchase $260.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

In related news, Director Pedro P. Granadillo sold 7,118 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $57.06, for a total value of $406,153.08. Following the completion of the transaction, the director now directly owns 31,663 shares of the company’s stock, valued at approximately $1,806,690.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Willaim P. Burke sold 13,193 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $54.04, for a total transaction of $712,949.72. Following the completion of the transaction, the chief financial officer now directly owns 27,227 shares of the company’s stock, valued at $1,471,347.08. The disclosure for this sale can be found here. Insiders sold a total of 32,869 shares of company stock worth $1,875,930 over the last 90 days. Company insiders own 1.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Haemonetics Co. (HAE) Position Reduced by Rutabaga Capital Management LLC MA” was first published by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.watchlistnews.com/haemonetics-co-hae-position-reduced-by-rutabaga-capital-management-llc-ma/1861184.html.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.